TG Therapeutics, Inc. (TGTX) stock
TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/3010% above fair value
$64.88−1.24 (-1.88%)
Close on Nov 19, 2026Market cap $9.93BP/E 23.7Yield –
TG Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
TG Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $799.54M, up 76.1% year over year. For fiscal 2025 it was $616.29M, up 87.3% from the year before. The highest annual figure on record is $616.29M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $616.29M | +87.3% |
| FY2024 | Dec 31, 2024 | $329.00M | +40.8% |
| FY2023 | Dec 31, 2023 | $233.66M | +8290.0% |
| FY2022 | Dec 31, 2022 | $2.79M | -58.4% |
| FY2021 | Dec 31, 2021 | $6.69M | +4300.7% |
| FY2020 | Dec 31, 2020 | $152.00K | 0.0% |
| FY2019 | Dec 31, 2019 | $152.00K | 0.0% |
| FY2018 | Dec 31, 2018 | $152.00K | 0.0% |
| FY2017 | Dec 31, 2017 | $152.00K | 0.0% |
| FY2016 | Dec 31, 2016 | $152.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $240.34M | +70.3% |
| Q1 FY2026 | Mar 31, 2026 | $204.92M | +69.6% |
| Q4 FY2025 | Dec 31, 2025 | $192.57M | +78.0% |
| Q3 FY2025 | Sep 30, 2025 | $161.71M | +92.8% |
| Q2 FY2025 | Jun 30, 2025 | $141.15M | +92.1% |
| Q1 FY2025 | Mar 31, 2025 | $120.86M | +90.4% |
| Q4 FY2024 | Dec 31, 2024 | $108.19M | +146.0% |
| Q3 FY2024 | Sep 30, 2024 | $83.88M | -49.4% |
| Q2 FY2024 | Jun 30, 2024 | $73.47M | +357.0% |
| Q1 FY2024 | Mar 31, 2024 | $63.47M | +713.5% |
| Q4 FY2023 | Dec 31, 2023 | $43.97M | +54863.8% |
| Q3 FY2023 | Sep 30, 2023 | $165.82M | +176298.9% |
| Q2 FY2023 | Jun 30, 2023 | $16.07M | +2606.1% |
| Q1 FY2023 | Mar 31, 2023 | $7.80M | +287.1% |
| Q4 FY2022 | Dec 31, 2022 | $80.00K | -96.6% |
| Q3 FY2022 | Sep 30, 2022 | $94.00K | -95.4% |
| Q2 FY2022 | Jun 30, 2022 | $594.00K | -61.6% |
| Q1 FY2022 | Mar 31, 2022 | $2.02M | +154.2% |
| Q4 FY2021 | Dec 31, 2021 | $2.32M | +6007.9% |
| Q3 FY2021 | Sep 30, 2021 | $2.03M | +5242.1% |
| Q2 FY2021 | Jun 30, 2021 | $1.55M | +3965.8% |
| Q1 FY2021 | Mar 31, 2021 | $793.00K | +1986.8% |
| Q4 FY2020 | Dec 31, 2020 | $38.00K | 0.0% |
| Q3 FY2020 | Sep 30, 2020 | $38.00K | 0.0% |
| Q2 FY2020 | Jun 30, 2020 | $38.00K | 0.0% |
| Q1 FY2020 | Mar 31, 2020 | $38.00K | 0.0% |
| Q4 FY2019 | Dec 31, 2019 | $38.00K | 0.0% |
| Q3 FY2019 | Sep 30, 2019 | $38.00K | 0.0% |
| Q2 FY2019 | Jun 30, 2019 | $38.00K | 0.0% |
| Q1 FY2019 | Mar 31, 2019 | $38.00K | 0.0% |
| Q4 FY2018 | Dec 31, 2018 | $38.00K | 0.0% |
| Q3 FY2018 | Sep 30, 2018 | $38.00K | 0.0% |
| Q2 FY2018 | Jun 30, 2018 | $38.00K | 0.0% |
| Q1 FY2018 | Mar 31, 2018 | $38.00K | – |
| Q4 FY2017 | Dec 31, 2017 | $38.00K | – |
| Q3 FY2017 | Sep 30, 2017 | $38.00K | – |
| Q2 FY2017 | Jun 30, 2017 | $38.00K | – |
See a number that looks wrong?